Acura Pharmaceuticals Inc
OTC:ACUR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Acura Pharmaceuticals Inc
Treasury Stock
Acura Pharmaceuticals Inc
Treasury Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Treasury Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Acura Pharmaceuticals Inc
OTC:ACUR
|
Treasury Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Treasury Stock
-$75.6B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-13%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Treasury Stock
-$43.6B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-10%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Treasury Stock
-$115B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Treasury Stock
-$63B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Treasury Stock
-$3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
Acura Pharmaceuticals Inc
Glance View
Acura Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of abuse deterrent, orally administered pharmaceutical products. The company is headquartered in Palatine, Illinois. The company went IPO on 2000-09-12. The firm has discovered and developed approximately three platform technologies, which can be used to develop multiple products. The firm's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The firm's Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The firm's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine tablets into methamphetamine.
